Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Tauranga boy Riaan Hamilton has cystic fibrosis. His mother Khali Hamilton hopes Trikafta will be funded after Pharmac's Respiratory Advisory Committee recommended funding Trikafta with high priority ...

Note: The verification e-mail to complete your account registration should arrive immediately. However, in some cases it takes longer. Don't forget to check your spam folder.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...

The U.S. IPO market is gaining momentum, with several issuers set for this week. Notably, defense contractor Karman Space & ...

Shortages of the medication which allows people with pancreatic cancer to digest food must be urgently addressed, the charity ...

Drugmakers — major beneficiaries of NIH-backed university research — have been largely silence on the Trump administration's cuts to agency research payments.

The 3D cell culture industry is poised for substantial growth from 2025 to 2035, driven by advancements in biotechnology and ...

The daughter of a key architect of Project 2025 benefitted from a life-changing drug — which was created with the help of the ...

Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...